Objective: As depressive disorders are highly heterogeneous, and as patients exhibit wide differences in clinical characteristics and comorbidities, we aim to examine whether and how demographic and clinical correlates affect healthcare costs for patients with depression in a real-world setting. Method: A national cohort of adult patients (n=216,557) who received treatment for depression was identified from the National Health Insurance Research Database in Taiwan. Factors associated with service use and healthcare costs over a 12-month period were explored, with a particular focus on past treatment history, comorbid physical illnesses, painful physical symptoms, and choice of initial antidepressants. Results: Depression severity, past treatment history, comorbid mental/physical illnesses, painful physical symptoms, and choice of initial antidepressants were found to be associated with healthcare costs in the following year, although the nature of the associations differed across cost categories. The presence of comorbid cardiovascular disease or certain painful physical symptoms at baseline was associated not only with higher non-psychiatric but also with higher psychiatric costs; moreover, patients with these comorbidities were shown to have increased use of psychiatric emergency and inpatient services. Conclusion: Healthcare costs for depression are affected by a number of clinical characteristics and comorbidities of patients. The importance of comorbid pain and cardiovascular conditions warrants further research.
Introduction
Unipolar depressive disorder was the fourth leading cause of disease burden among all diseases in 2002 (Mathers and Loncar, 2006) and is predicted to become the leading cause in 2015 (WHO 2008) . The total direct healthcare costs of depression in Taiwan, as in many other countries, rose by 50% over the period of -2002 (Chan et al., 2006 ; the prevalence of antidepressant use also doubled from 1997 to 2004 (Chien et al., 2007) . This could imply an increase in the need for depression treatment, a reduction in the treatment gap, or over-provision of care. Given the anticipated rise in the future healthcare costs for patients with depression, it would help inform decision-making to assess the impact of depression treatment from an economic perspective.
Depressive disorders comprise a group of heterogeneous conditions. The extent to which treatment history, comorbidities of physical/mental illnesses, and choice of antidepressants can influence healthcare costs remains to be determined. Depression is known to be associated with a variety of physical conditions (Katon 2003) of whom cardiovascular diseases (CVD) and painful physical symptoms (PPS) warrant further investigation. Depression and CVD are projected to be the first and second leading causes of health-related burden in 2015 (WHO 2008) , and there is accumulating evidence suggesting close interrelationships between these highly-prevalent conditions (Sorensenf et al., 2005; Thombs et al., 2006) : for instance, depressive symptoms have been found to be a risk factor for cardiac events in patients with coronary heart disease (Barth et al., 2004; van Melle et al., 2004) . To assess the economic impact of treatment for depression, PPS should also be carefully considered. Previous studies have revealed high prevalence of pain complaints in depressed patients (Bair et al., 2003; Husain et al., 2007; Ohayon and Schatzberg, 2003) and outcomes of treatment for depression may be poorer in the presence of PPS (Fava et al., 2004; Gameroff and Olfson, 2006; Leuchter et al., 2010) . Furthermore, individual antidepressants have been shown to have a wide range of cardiovascular effects (Taylor 2008) , and antidepressants may differ in the effectiveness for the relief of PPS. Therefore, the presence of these co-occurring CVD and PPS may influence the choice of antidepressants and healthcare utilization, with potential impact on healthcare costs.
The current study, conducted in a real-world setting, seeks to measure healthcare costs for people with depression using claims data from the National Health Insurance Research Database (NHIRD) in Taiwan. The objective of this study is to identify which demographic and clinical characteristics and comorbidities are associated with total healthcare costs, as well as costs for specific groups of services, with a particular focus on comorbid pain and cardiovascular diseases.
Materials and methods

Data
Taiwan is a country with a population of around 23,000,000. th revision, clinical modification diagnoses (ICD-9-CM). In this study, the included subjects were identified from the NHIRD. The index date was defined as the date on which the subject was first prescribed an antidepressant for a diagnosis of depressive disorder in 2003. Data on all NHI information for each subject were extracted for the two-year period spanning the index date (one year preceding, and one year following).
Participants
All subjects in NHIRD meeting the following criteria were included:  At least one prescription for an antidepressant for treatment of major depressive disorder (MDD) (ICD-9-CM codes: 296.2x, 296.3x) or minor depression (ICD-9-CM codes: 311.xx, 300.4x) in 2003.  Data available for a minimum of 12 months before and after the index date.  Age 18 years or over on the index date. A subsample of patients with newly-diagnosed depression was also identified within this overall sample, which was operationally defined as individuals who were free of antidepressant use or a depression diagnosis for a minimum of 12 months before the index date.
Demographic and clinical information
Demographic and clinical data were extracted, including age, gender, diagnosis of depressive disorders, and initial choice of antidepressants on the index date. Participants were further grouped according to past treatment history, i.e., newly-diagnosed depression and non-newly-diagnosed depression.
Baseline characteristics were traced back for all subjects for the 12 months prior to the index date, including comorbid mental disorders, physical illnesses (CVD, diabetes mellitus (DM), chronic obstructive pulmonary disease (COPD), renal diseases, and cancer), PPS (backache, headache, musculoskeletal and gastrointestinal pain), and healthcare utilization/expenditure.
Service use and costs
Service use components extracted from the NHIRD included outpatient services, emergency attendances, and inpatient stays. Service use over the 12-month study period was described by the percentage of patients with at least one unit of service use and the mean number of service contacts for the whole sample. Medication use regarding prescriptions of antidepressants was identified. All costs over the 12-month study period were calculated from the actual claims data, were described by service categories, and expressed in 2003-4 US dollars.
Data analysis
Sociodemographic data, clinical characteristics, baseline healthcare utilization/expenditure, and initial antidepressant treatment were described for the overall sample and compared between newly-diagnosed depression and non-newly-diagnosed depression groups.
To identify characteristics predictive of healthcare costs over the 12-month period, a multivariate generalized linear regression model with a log link and gamma variance function was employed (McCullagh and Nelder, 1989) . Separate models were run for total healthcare costs, psychiatric costs, and non-psychiatric costs. And to measure the model fit, the root mean square error (RMSE) (Zheng and Agresti, 2000) for each model was computed after excluding 0.1% of subjects with extremely large predicted values in costs. The independent variables considered in these models were age, sex, index depression diagnosis, past treatment history, initial choice of antidepressants, baseline comorbid mental/physical disorders, baseline PPS, and baseline total healthcare expenditure. These variables were first selected using a univariate model and those significant at the 5% level were included subsequently. A backward selection process was then applied to obtain the final multivariate model, using a 5% level of significance. Subsequently, such analyses were performed in a subsample of subjects with newly-diagnosed depression as they were a group which warrants further investigation. This was also to determine the influence of past treatment history on the findings from the overall sample.
As use of psychiatric emergency and/or inpatient services may be indicators for patients who require more intensive care, thus generating higher costs, we examined variations in use of these two key services in further analyses. With use of psychiatric emergency services and use of psychiatric inpatient services as dependent variables, independent variables were entered in a multivariate logistic regression with a forward LR (likelihood ratios) method to explore predictors of use over the 12-month study period. A p-value of 0.05 was considered significant for all statistical analyses, which were performed using SPSS version 17.0 (Chicago, IL, USA).
Results
A total of 216,557 adult individuals met the inclusion criteria, including a subsample of 84,577 persons with newly-diagnosed depression. Table 1 shows that for the overall sample, 61.9% were females and 18.7% were aged 65 years or over on the index date. Regarding baseline comorbidities, 26.9% had CVD, 10.9% had DM, and 15.2% had COPD. Comorbid PPS rates were particularly high for both the overall sample and the subsample of individuals with newly-diagnosed depression. At the index visit, 45.6% of the overall sample were prescribed selective serotonin reuptake inhibitors (SSRIs) and 8.6% prescribed serotonin norepinephrine reuptake inhibitors (SNRIs). Only 3.1% of patients received other newer antidepressants (bupropion and mirtazapine).
Patients with newly-diagnosed depression were younger and had a greater proportion of females compared to those with non-newly-diagnosed depression. They had lower rates of comorbid physical/mental illnesses and lower prevalence of PPS. Health service utilization at baseline was lower as well. A higher proportion of them were prescribed newer generation antidepressants.
Service use and costs
Service use data are summarized in Table 2 . Of the overall sample, 85.1% had used psychiatric outpatient services over the 12-month study period. Over the same period, 5.0% of them had been admitted to psychiatric wards for inpatient treatment and 1.6% had psychiatric emergency attendances.
Costs of outpatient contacts in total accounted for 63.6% of total healthcare costs for these patients. And overall expenditures on psychiatric services were around 29.2% of the total healthcare costs. Table 3 reveals that higher total healthcare costs were associated with older age, male gender, an index diagnosis of MDD, non-newly-diagnosed depression, and having CVD, DM, COPD, renal disease, cancer or PPS at baseline.
Total healthcare costs
Use of SNRIs, other newer generation antidepressants and use of multiple antidepressants were related to higher costs compared to use of SSRIs at the index date. Lower costs were observed for those using tricyclic antidepressants (TCAs), flupentixol/melitracen, and other older antidepressants (maprotiline, moclobemide, and trazodone). The analysis on the subsample of newly-diagnosed depression revealed similar results with those from the full sample. Regarding the model fit, RMSE of the model for total costs was 1316. The predicted mean of total costs was 1925 US dollars versus the actual mean costs 1731 US dollars.
Non-psychiatric healthcare costs
Older age, and male gender were related to higher non-psychiatric costs in the following year (Table 4 ). Compared to patients with history of either an antidepressant treatment or a depression diagnosis, those with newly-diagnosed depression had higher non-psychiatric costs. Patients with an index diagnosis of MDD or a baseline comorbid mental disorder were associated with lower costs, with the only exceptions being alcohol, substance misuse, multiple drugs-related mental disorders and dementia. The presence of a comorbid physical illness or PPS at baseline was related to higher non-psychiatric costs.
Patients prescribed older antidepressants had higher non-psychiatric costs in the following year compared to those prescribed SSRIs while patients prescribed newer antidepressants such as SNRIs or bupropion/mirtazapine had non-psychiatric costs that did not differ significantly. The RMSE of the model was 4380. And the predicted mean of non-psychiatric costs was 1452 US dollars while the actual mean cost was 1226 US dollars.
Psychiatric healthcare costs
As shown in Table 4 , male gender was associated with higher psychiatric costs in the following year. Not surprisingly, patients having an index diagnosis of MDD had increased costs as did those with baseline comorbid mental disorders. Patients with newly-diagnosed depression had lower psychiatric costs compared to those who had been diagnosed prior to the index date. Younger age was shown to be related to higher psychiatric costs.
Use of newer generation antidepressants or multiple antidepressants prescribed on the index date were related to higher psychiatric costs compared to those prescribed SSRIs, while use of older antidepressants was related to lower costs. Among comorbid physical illnesses, CVD was the only one found to increase psychiatric costs. And among PPS, only pain complaints relating to the central nervous system (CNS), i.e., headache/dizziness/or migraine, were related to higher psychiatric costs. The RMSE of the model was 1074. The predicted mean of psychiatric costs was 577 US dollars and the actual mean was 506 US dollars.
Use of psychiatric emergency and inpatient services
Younger age, male gender, a diagnosis of MDD or certain comorbid mental disorders were more likely to lead to psychiatric emergency attendances and hospitalizations (Table 5 ). CVD or COPD was related to higher odds of using psychiatric emergency and hospitalization services. Headache/dizziness/or migraine complaints at baseline were associated with an increase in the odds of using psychiatric emergency and hospitalization services as well.
Discussion
This study provided new evidence on the associations between comorbidities, service use, and healthcare costs for patients with depression. Although the nature of the associations differed across cost categories, the multivariate models revealed that age, gender, depression severity, past treatment history, comorbid mental/physical illnesses, PPS, and choice of initial antidepressants were all associated with healthcare costs in the following year. Factors including comorbid CVD and PPS were further explored to understand patterns of variation in psychiatric emergency and inpatient service use over the 12-month study period.
Demographic characteristics
Although previous studies have suggested that medical costs are higher for women than men (Owens 2008; Woolhandler and Himmelstein, 2007) , this study found a different result: for patients with depressive disorders, and taking into account other influences on costs, male gender was shown to be associated with higher costs for both non-psychiatric and psychiatric healthcare services.
There have been few recent studies that specifically examined the association between gender and healthcare utilization/expenditure for patients with depressive disorders. A study of elderly patients with psychiatric diagnoses suggested that men had more emergency attendances and had greater inpatient costs than women, which led some investigators to propose that when men eschew regular visits to physicians, it is likely that emergency or inpatient treatment may be required as illness progresses (Husaini et al., 2002) . Consistently, male patients were shown to be associated with increased use of psychiatric emergency and inpatient services in the current study. One interpretation of our results is therefore that male patients with depression may enter the healthcare system later in the disease course, by which time their illness is more severe, thus generating higher costs.
Comorbid cardiovascular disease
Among the frequently co-occurring physical illnesses considered in this study, CVD was the only one shown to increase not only non-psychiatric but also psychiatric costs. Depression has been revealed to be an independent risk factor for the future onset, progression, and recurrence of CVD (Carney et al., 1988; Ferketich et al., 2000; Nicholson et al., 2006; Rugulies 2002; Sesso et al., 1998; Wassertheil-Smoller et al., 2004) , which can be mediated both by poor health behavior and by the pathophysiological correlates of depressive symptoms, e.g., neuroendocrine and inflammatory activation (Frasure-Smith and Lesperance, 2010; Rozanski et al., 2005) . Additionally, individual antidepressants have a wide range of cardiovascular effects which may affect cardiovascular-related morbidity and mortality (Coupland et al., 1997; Taylor 2008; Vieweg and Wood, 2004) ; it seems likely that the co-existence of CVD and depression may impact patients' physical conditions and their non-psychiatric costs.
As well, we found that the presence of comorbid CVD was related to higher odds of using both psychiatric emergency and hospitalization services which was consistent with the finding of increased psychiatric costs in these patients. CVD has been shown to be correlated with certain lifestyles, alcohol consumption, and personality traits (e.g., Type D personality), some of which seem to be highly correlated with use of psychiatric services. For instance, Type D has been conceptualized as a personality trait comprising negative affectivity and social inhibition that often co-occurs with depression in patients with coronary artery disease, and that may inhibit remission of depressive symptoms (Albus et al., 2011; Denollet et al., 2010) . Although it can only be speculative, the identified association between the presence of CVD and increased psychiatric service utilization/expenditure in this study may be understood as being indirectly influenced by these unmeasured and potentially associated factors.
Painful physical symptoms
The relationships between depression and pain are complex with similar brain areas regulating both mood and the affective components of pain (Giesecke et al., 2005) . High prevalence of pain complaints has been reported in patients with depression (Bair et al., 2003; Husain et al., 2007; Ohayon and Schatzberg, 2003) . Our results added to this evidence in finding a high percentage of comorbid PPS in patients with newly-diagnosed depression, which supports findings from previous studies that pain usually appears before the development of MDD (Ohayon and Schatzberg, 2010) . On the other hand, increasing pain interference has been reported to be associated not only with higher odds of having depressive disorders (Barry et al., 2012) , but also with adverse impact on poor treatment response (Bair et al., 2004) . Pain complaints seem to be characteristic of depression that is more severe and refractory to antidepressant treatments, as evidenced by higher healthcare utilization, and higher costs (Gameroff and Olfson, 2006) .
As most previous studies were based on highly selective samples and did not consider many comorbidities, it is unclear whether these results could be generalized to larger samples of patients in a real-world setting, and to what extent other factors such as comorbid mental/physical illnesses would contribute to the possible association between PPS, healthcare utilization, and treatment outcome. In the current study, we concurred with previous studies in suggesting that the presence of PPS was associated with higher total healthcare costs in the following year; this remained true for those with newly-diagnosed depression. In addition, analyses based on origins of pain complaints found that the co-existence of PPS was generally associated with higher non-psychiatric costs but lower psychiatric costs, with headache being the only exception: unlike pain complaints over other somatic systems, having headache was associated with higher psychiatric costs and greater odds of using psychiatric emergency and inpatient services. A recent study suggested the existence of differences in separate pain modalities in relation to depression, and that a closer relationship may exist between MDD and neuropathic pain than non-neuropathic pain (Ohayon and Stingl, 2012) . It seems possible that a more direct relationship might exist between depression and pain complaints over the central nervous system than PPS from other somatic systems as our data might suggest.
Antidepressant choice
The current study showed that initial choice of antidepressants appears to be associated with total healthcare costs in the following year. Compared to patients prescribed SSRIs, those prescribed older antidepressants had lower total and psychiatric costs, whilst patients prescribed SNRIs, and other newer antidepressants had higher total and psychiatric costs. However, to a large extent these differences may be attributed to physician selection: patients prescribed older antidepressants were more likely to suffer minor depression, to be older, and to have more PPS and physical comorbidities at baseline. Contrarily, patients prescribed newer antidepressants were more likely to have MDD, to be younger, and to have fewer baseline physical comorbidities (not shown in this paper). These distinctive characteristics suggest the existence of physician selection based on patients' clinical characteristics that unfortunately could not be fully accounted for by the adjustment factors in our analyses.
Further support could be drawn from the comparisons between cost models: as seen in Table 4 , patients prescribed SNRIs and other newer antidepressants were similar to those prescribed SSRIs in non-psychiatric costs, whilst patients prescribed TCAs and other older antidepressants generally had higher non-psychiatric costs. These results could be interpreted as showing that there were differences especially in physical comorbidities between these two groups of depressed patients. Previous database analyses have also suggested that SSRI users may have higher depression-related service expenditures but lower non-depression-related service expenditures than TCA users (Pan et al., 2012) . Along with these previous findings, our results suggest that depressed patients prescribed older antidepressants may be different from those prescribed SSRIs, SNRIs, and other newer antidepressants in terms of clinical features of depression and comorbidities.
Limitations and conclusions
As service use data contained in the NHIRD includes only health services provided by the NHI system in Taiwan, the perspective of the current analysis was relatively limited, and we were not able to analyze wider economic impacts. Confounding or selection bias due to the nonrandomized study design should be borne in mind while interpreting the results, although the real-world context and whole-country coverage are strengths, especially when analyzing the inherent heterogeneity of clinical presentations and patient characteristics and their influences on help-seeking behaviors, clinical outcomes, and costs.
In conclusion, the current study-based on a large national database-suggests a set of significant correlates of healthcare costs for depressed patients. Male gender and a diagnosis of MDD were significantly associated with higher total healthcare costs. The baseline comorbidities of CVD and headache were associated not only with higher non-psychiatric but also with higher psychiatric costs; moreover, these comorbidities were related to increased use of psychiatric emergency and inpatient services in the following year. *All comparisons between newly-diagnosed and non-newly-diagnosed depression were statistically significant with a p< 0.001 (chi-squared test was used for categorical variables and independent t-test for continuous variables). 
